Burns Matteson Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Burns Matteson Capital Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$424K	Buy	+26,474	New	+$438K	0.13%	133

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Burns Matteson Capital Management's TAK Position: Q2 2026 in Review

Burns Matteson Capital Management opened a new position in Takeda Pharmaceutical (TAK) in Q2 2026: 26,474 shares worth $424K. The stake represents 0.13% of the portfolio and ranks #133 among its holdings.

378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Burns Matteson Capital Management held 26,474 shares of Takeda Pharmaceutical worth $424K as of Q2 2026.
Takeda Pharmaceutical was a new Burns Matteson Capital Management position in Q2 2026.
Takeda Pharmaceutical made up 0.13% of Burns Matteson Capital Management's portfolio in Q2 2026, its #133 holding.
378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Burns Matteson Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.